Patent ID: 11896682
Assignee: REGENERON PHARMACEUTICALS, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C  G | IPC A  C

Claim 22:
23. A method for treating a subject having a solid tumor comprising:
(a) determining that the solid tumor is MET-positive, comprising:
(i) administering a radiolabeled antibody conjugate to the subject in need thereof, wherein the conjugate comprises:
an antibody or antigen-binding fragment thereof that binds MET, wherein the antibody or antigen-binding fragment thereof comprises three HCDRs in an HCVR having an amino acid sequence selected from the group consisting of SEQ ID NO: 2, 10, 18, 26, 34, 42, 50, 58, 66, 74, 82, 90, 98, 106, 114, 122, and 130; and three LCDRs in an LCVR having an amino acid sequence of SEQ ID NO: 138; and
(ii) imaging localization of the radiolabeled antibody conjugate in the tumor by positron emission tomography (PET) imaging, wherein presence of the radiolabeled antibody conjugate in the tumor indicates that the tumor is MET-positive; and

(b) administering one or more doses of an inhibitor of the HGF/MET signaling pathway to the subject in need thereof.